Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study)
Our data showed that BIC/FTC/TAF demonstrated high virologic and immunologic efficacy and an excellent safety profile.
Authors
- Carmela Pinnetti (ORCID: https://orcid.org/0000-0003-1350-4032)
- Giulia Del Duca (ORCID: https://orcid.org/0009-0004-3408-3817)
- Maria Maddalena Plazzi (ORCID: https://orcid.org/0000-0002-1574-1552)
- Andrea Antinori (ORCID: https://orcid.org/0000-0003-2121-4684)
- Massimo Tempestilli (ORCID: https://orcid.org/0000-0003-3107-7441)
- Federico De Zottis (ORCID: https://orcid.org/0000-0001-9040-2000)
- Alessandra Vergori (ORCID: https://orcid.org/0000-0001-6944-0686)
- Marisa Fusto
- Valentina Mazzotta (ORCID: https://orcid.org/0000-0002-0240-7504)
- Ilaria Mastrorosa (ORCID: https://orcid.org/0000-0003-1944-662X)
- Marta Camici (ORCID: https://orcid.org/0000-0002-6624-7917)
- Roberta Gagliardini
- Sandrine Ottou
- Simone Lanini
- Elisabetta Grilli
- Annalisa Mondi
- Rita Bellagamba
Institutions
- University of Udine (IT)
- Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT)
- Ospedale Santa Maria della Misericordia di Udine (IT)
Publication Details
- Journal
- International Journal of Infectious Diseases
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1016/j.ijid.2025.107961
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Gilead Sciences
- Ministero della Salute